Prevention of Bladder Cancer Recurrence With the Botanical Formula LCS103: A Case Series Study

Area of Science:

• Oncology
• Urology
• Botanical Medicine

Background:

• Non-muscle invasive bladder cancer (NMIBC) has high recurrence rates, often requiring repeated intravesical treatments.
• Existing treatments like BCG have limitations, necessitating exploration of novel therapeutic approaches.
• The botanical formula LCS103 shows preclinical anti-cancer activity against bladder cancer cells.

Purpose of the Study:

• To evaluate the clinical efficacy and safety of the botanical formula LCS103 in bladder cancer patients.
• To assess the impact of LCS103 on tumor recurrence rates in patients with non-muscle invasive bladder cancer (NMIBC) and metastatic disease.
• To investigate the effect of LCS103 on urological symptoms and overall wellbeing.

Main Methods:

• Retrospective analysis of 20 bladder cancer patients (18 NMIBC, 2 metastatic) treated with LCS103 alongside conventional oncology care.
• Treatment duration ranged from 14 months to 16 years.
• Data collected on tumor recurrence, urological symptoms, fatigue, and adverse events.

Main Results:

• Only 3 patients (15%) experienced a single tumor recurrence after initiating LCS103, compared to 11 patients (55%) pre-treatment.
• The majority of patients reported decreased severity of urological symptoms (pain, frequency, urgency, nocturia).
• Patients also reported improvements in weakness, fatigue, and general wellbeing, with no adverse events linked to LCS103.

Conclusions:

• LCS103 demonstrated a potential to reduce tumor recurrence in bladder cancer patients.
• The botanical formula may improve urological symptoms and overall quality of life.
• Further prospective randomized trials are warranted to validate these preliminary findings.